舒泰神股价跌5.17%，东方阿尔法基金旗下1只基金重仓，持有23.95万股浮亏损失39.51万元

Group 1 - The core point of the news is that Shutaishen's stock has experienced a significant decline, dropping 5.17% to 30.27 CNY per share, with a total market capitalization of 14.462 billion CNY and a cumulative drop of 18.78% over the last five days [1] - Shutaishen (Beijing) Biopharmaceutical Co., Ltd. specializes in the research, production, and sales of biological products and some chemical drugs, with its main revenue sources being the injection of mouse nerve growth factor (Sutai) at 59.17%, compound polyethylene glycol electrolyte powder at 33.19%, and others at 7.63% [1] Group 2 - From the perspective of major fund holdings, the Dongfang Alpha Fund has increased its stake in Shutaishen, holding 239,500 shares, which represents 6.08% of the fund's net value, ranking it as the eighth largest holding [2] - The Dongfang Alpha Health Industry Mixed Fund A (024357) has incurred a floating loss of approximately 395,100 CNY today and a total floating loss of 1.7672 million CNY during the five-day decline [2] - The fund manager, Meng Yu, has been in charge for 1 year and 362 days, with the fund's total asset size at 306 million CNY and a best return of 18.32% during the tenure [2]